4.8 Article

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWPI inhibitory pathway

Journal

SCIENCE
Volume 364, Issue 6441, Pages 651-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aau0159

Keywords

-

Funding

  1. NIH [R01 CA82328, R35 CA197529]
  2. Postdoctoral Research Abroad Program Fellowship, Taiwan National Science Council (NSC)
  3. DOD Prostate Cancer Research Program (PCRPP) Postdoctoral Training Award [W81XWH-16-1-0249]
  4. National Breast Cancer Foundation Career Development Fellowship

Ask authors/readers for more resources

Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. Polyubiquitination by the ubiquitin E3 ligase WWP1 (WW domain-containing ubiquitin E3 ligase 1) suppressed the dimerization, membrane recruitment, and function of PTEN. Either genetic ablation or pharmacological inhibition of WWP1 triggered PTEN reactivation and unleashed tumor suppressive activity. WWP1 appears to be a direct MYC (MYC proto-oncogene) target gene and was critical for MYC-driven tumorigenesis. We identified indole-3-carbinol, a compound found in cruciferous vegetables, as a natural and potent WWP1 inhibitor. Thus, our findings unravel a potential therapeutic strategy for cancer prevention and treatment through PTEN reactivation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available